American College of Physicians’ Post

NEW from #ESMOGI2024 | Safety concerns of using #HER2-targeting therapies in #gastrointestinalcancers 🎥 🇩🇪 Sara Lonardi, MD, Veneto Institute of Oncology, addresses safety considerations when utilizing #HER2-directed therapies in #gastrointestinalcancers While rare, there is a risk of developing interstitial #lungdisease (ILD) with #trastuzumab #deruxtecan 💡 Prompt recognition of grade 1 toxicity symptoms is crucial, following clinical guidelines that recommend discontinuing treatment until ILD resolves to grade 0, followed by corticosteroids 💡 Escalation to grade 2 toxicity necessitates discontinuation of trastuzumab deruxtecan 💡 Managing other toxicity symptoms such as nausea and vomiting with anti-emetic medications is feasible, but maintaining the balance between symptom relief and preserving the efficacy of anticancer treatment remains pivotal Learn more 👉 https://lnkd.in/eDMaNa5X #VJOncology #Oncologynews

Following only three cycles of Pola-R-CHP therapy (consisting of Polatuzumab vedotin, Rituximab, Doxorubicin, Cyclophosphamide, and Prednisolone), a 25 y.o patient diagnosed with large B-cell lymphoma with germinal center B-cell-like phenotype achieved a complete metabolic response. On December 20, the patient underwent a baseline 18F-FDG PET/CT scan, revealing a sizable and highly metabolically active FDG tissue mass characterized by invasive growth. The mass extended from the upper abdomen through the diaphragm to the mediastinal region, with a Deauville 5PS score. Following precisely two months and three cycles of therapy, the interim PET/CT scan demonstrated total metabolic resolution of the thoracoabdominal mass, with no FDG uptake exceeding background levels. The Deauville score was 1PS, indicating a complete metabolic response. #medical #nuclearmedicine #nucmed #molecularimaging #petct #fdg #lymphoma #haematology

Anti-tumor necrosis factor-alpha (TNF-α) therapies have revolutionized clinical care, offering hope to patients with conditions like rheumatoid arthritis, Crohn's disease, and more. Learn about the historical development and future potential of these therapies, including their role in treating COVID-19 and certain types of cancer. Read the full article: https://lnkd.in/eACFxxii #AutoimmuneDiseases #MedicalAdvancements #TNFTherapies 🩺💊 #Anogen

A new study by Israeli scientists has reported obesity/diabetes treatment drugs from the glucagon-like peptide-1 receptor agonists (GLP-1RA) class do not increase the risk of pancreatic cancer. They emphasised this is an important finding as type 2 diabetes is associated with a higher risk of most cancers. 👉 Follow https://lnkd.in/gnpUqRhS to read the complete article at #aestheticmedicalpractitionermagazine.⁠ ⁠ ⁠ #aestheticmedicine #aestheticmedicinenews #aestheticmedicalpractitioner #cosmeticsurgery #plasticsurgery #diabetesresearch

It is also known as metastatic breast cancer and is considered an advanced stage of the disease. Read more 👉 https://lttr.ai/ARfa2 #Cdk46Inhibitor #AromataseInhibitors #HormoneReceptorPositive #Pharmacist #Healthcare #Quality #Chemotherapy #GenomicComplexityDetected #BloodCopyNumberBurden #PredictPoorOutcomes

🚀 **Breaking Down the Big 3 in 2nd Generation Antiandrogen Therapy: Darolutamide, Enzalutamide, and Apalutamide** 🚀 In the evolving landscape of prostate cancer treatment, understanding the side effects of antiandrogen therapies is crucial for optimizing patient care. Here’s a snapshot of how Darolutamide, Enzalutamide, and Apalutamide stack up: 🔬 **Enzalutamide**: - **Known For**: Fatigue and seizures. - **Insight**: While highly effective, it’s important to monitor for these side effects closely. Patients may need extra support to manage fatigue and ensure seizure risks are addressed. 🌟 **Apalutamide**: - **Known For**: Rash and hypothyroidism. - **Insight**: These side effects require vigilant monitoring. Regular skin checks and thyroid function tests can help mitigate complications and keep treatment on track. 💡 **Darolutamide**: - **Known For**: Minimal drug-drug interactions due to its weak inhibition of CYP3A4. - **Insight**: Ideal for patients needing fewer drug interactions. However, be aware of the need for renal and hepatic dose adjustments. Understanding these nuances helps in tailoring treatment plans and improving patient outcomes. Let’s continue to advance our knowledge and refine our approaches in managing prostate cancer. 🌐 #ProstateCancer #Oncology #Healthcare #Pharmacology #PatientCare #CancerTreatment

New issue online!🌿 Unveiling CXCR2 as a promising therapeutic target in #renalcellcarcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001 ----------------------- In clear cell renal cell carcinoma (ccRCC), first-line treatment combines nivolumab (anti-PD-1) and ipilimumab (anti-CTLA4), yielding long-term remissions but with only a 40% success rate. This study by Gilles Pagès, Maeva Dufies et al. explored the potential of enhancing ccRCC treatment by concurrently using CXCR2 inhibitors alongside immunotherapies. Read here⤵️ https://lnkd.in/dBWfcbc7 #Tumorassociatedmacrophages #Immunotherapiesresistance #CXCR2inhibitors #Nivolumab #Ipilimumab IFO - Istituto Nazionale Tumori Regina Elena - Istituto Dermatologico San Gallicano

CytoAgents’ drug candidate, CTO1681, prevents and treats Cytokine Release Syndrome (CRS), which is a dangerous side effect to CAR T-cell therapy in oncology. CTO1681 targets the NF-kB signaling pathway via the activation of the EP4 receptor, which reduces NF-kB signaling, but does not shut it down completely. This, in turn, modulates cytokine production, resulting in reduced inflammation, while still allowing for a functioning immune system. Learn more about CRS and CTO1681 here: https://lnkd.in/eFasArrf #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

A very interesting #article on Medscape #Oncology; 'New #Drug #Approvals Are the Wrong #Metric for #Cancer #Policy'. Link: https://lnkd.in/djy_UjZy I'll just #quote the introductory #paragraph here, and leave the rest of this powerful #commentary for you to enjoy #reading from the #link above. "How should we define #success in cancer policy — what should the endpoint be? It's debatable. Is it fewer cancer #deaths? Perhaps improved #access to #therapies or a reduction in #disparities? One thing I know with certainty: The number of new cancer #drugs approved by the US #FDA is not and should not be our primary #endpoint in and of itself. I'll go a step further: It is not even a surrogate #marker for success. The number of newly approved drugs is a #meaningless metric. Here's #why." #Health #Healthcare #Care #Medicine #Pharmacy #Pharmaceuticals #Equity #Coverage #Reimbursement

On April 23, 2024, the FDA granted accelerated approval to Ojemda (tovorafenib) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This represents the first FDA approval of a systemic therapy for the treatment of patients with pediatric LGG with BRAF rearrangements, including fusions. Tovorafenib is a selective, central nervous system–penetrant, type II RAF inhibitor with activity against monomeric and dimeric forms of RAS signaling. Unlike type I BRAF inhibitors, tovorafenib does not lead to paradoxical activation of the MAPK pathway. Tovorafenib is available as an immediate release tablet or as an oral suspension. The recommended tovorafenib dose based on body surface area (BSA) is 380 mg/m2 orally once weekly (the maximum recommended dosage is 600 mg orally once weekly) with or without food until disease progression or intolerable toxicity. A recommended dosage for patients with BSA less than 0.3 m2 has not been established. #Cancer #Oncology #Glioma #LowGradeGlioma #LGG #Moffitt #MoffittCancerCenter Moffitt Cancer Center